References |
IKNL(1); Austin Lunney. Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX, USA (2); L.M. de Almeida Carvalho et al. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib. Oncology. 2019 (3);
|